You are here: Industry Insights > Novavax

News List

PolyPeptide Group Partners with Novavax on COVID-19 Vaccine contractpharma
June 05, 2020
Will manufacture critical intermediates of Matrix-M adjuvant for vaccine candidate.
AGC Biologics to produce Covid-19 vaccine adjuvant for Novavax pharmaceutical-technology
June 05, 2020
Novavax has selected AGC Biologics, a contract development and manufacturing organisation (CDMO), for large-scale manufacturing of an adjuvant for its Covid-19 vaccine candidate, NVX-CoV2373.
Novavax gets US defense funding for its COVID-19 vaccine expresspharma
June 05, 2020
The US-based company said the deal includes the delivery of 10 million doses of its COVID-19 vaccine - NVX‑CoV2373 - to the DoD this year.
Novavax Selects AGC Biologics to Manufacture Novel COVID-19 Vax contractpharma
June 04, 2020
To provide large-scale GMP production of Matrix-M, the adjuvant component of Novavax’ coronavirus vaccine candidate, NVX-CoV2373.
Novavax buys Praha Vaccines for Covid-19 vaccine manufacturing pharmaceutical-technology
May 29, 2020
Biotechnology firm Novavax has acquired Czech Republic-based Praha Vaccines for approximately $167m to support the manufacture of its Covid-19 vaccine candidate, NVX‑CoV2373.
Novavax Expands Large-Scale Global Manufacturing Capacity contractpharma
May 28, 2020
Acquires Praha Vaccines in Czech Republic; annual operating capacity of over 1 billion doses of COVID-19 vaccine antigen.
Novavax launches trial of coronavirus vaccine candidate pharmatimes
May 26, 2020
As of this morning – Tuesday May 26 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 261,184 with 36,914 deaths.
CEPI invests $384m in Novavax COVID-19 vaccine candidate europeanpharmaceuticalreview
May 13, 2020
CEPI has announced that its funding for the Novavax COVID-19 vaccine candidate will go towards Phase I and Phase II trials as well as manufacturing costs.
CEPI to provide up to $388m for Novavax’s Covid-19 vaccine pharmaceutical-technology
May 13, 2020
The Coalition for Epidemic Preparedness Innovations (CEPI) has agreed to provide up to $384m in funding to support Novavax in the development and manufacturing of Covid-19 vaccine candidate, NVX-CoV2373.
Emergent Signs Manufacturing Agreement with Novavax contractpharma
April 06, 2020
Emergent BioSolutions has entered an agreement with Novavax to provide molecule-to-market contract development and manufacturing services to produce Novavax’s NanoFlu.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page